Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Companyâ€™s main products include CMAB009 Enlituo (cetuximab Î² injection), CMAB007 Aomaishu (Omalizumab Î± for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Companyâ€™s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

Employees

389

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/06/26	HK$0.4400	+7.32%	406,000
23/06/26	HK$0.4100	0.00%	22,000
22/06/26	HK$0.4100	+7.89%	1,270,000
18/06/26	HK$0.3800	-1.30%	190,000
17/06/26	HK$0.3850	0.00%	0

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. Other stock markets 12:08:03 24/06/2026 +04			5-day change	1st Jan Change
0.4400 ^HKD	+7.32%		+14.29%	-12.00%

06-09	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
06-09	Mabpharm's Application for Osteoporosis Drug Approved in China	MT

Market Cap	1.46B 1.69B 216M 189M 175M 163M 306M 20.43B 311M 2.1B 811M 10.02B 810M 792M 34.84B	P/E 2024	-8.48x	P/E 2025	44.9x
Enterprise Value	1.68B 1.94B 248M 218M 200M 188M 352M 23.46B 358M 2.41B 932M 11.51B 930M 910M 40.01B	EV / Sales 2024	5.06x	EV / Sales 2025	3.2x
Free-Float	22.82%	Yield 2024 *	-	Yield 2025	-

06-09	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
06-09	Mabpharm's Application for Osteoporosis Drug Approved in China	MT
03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million	RE
12-05	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
31/10/25	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025	CI
28/08/25	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/03/25	Mabpharm Shrinks Loss by 39% in 2024	MT
26/03/25	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/01/25	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator	MT
02/01/25	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)	CI
27/12/24	Mabpharm Limited Announces Approval from the Indonesian National Agency of Drug and Food Control on the Marketing Authorization of its Core Product, CMAB008 (Infliximab for Injection)	CI
28/08/24	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2024	CI

13/11/23	Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
20/07/21	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
30/04/21	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21/04/21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
12/04/21	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU

Mabpharm Limited Stock

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Valuation: Mabpharm Limited

Chart: Mabpharm Limited

Latest news : Mabpharm Limited

Press Releases: Mabpharm Limited

Quotes and Performance

Course Extremes

Managers and Directors: Mabpharm Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+7.32%
1 week	+14.29%
Current month	+11.39%
1 month	+3.53%
3 months	-22.81%
6 months	-18.52%
Current year	-12.00%

1 week	0.32	0.45
1 month	0.31	0.51
Current year	0.31	0.81
1 year	0.31	0.88
3 years	0.25	0.94
5 years	0.25	1.4
10 years	0.25	1.8

Manager	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	57	28/10/2020
Sheng Hou PRN	Corporate Officer/Principal	49	01/12/2023
Jing Tao PRN	Corporate Officer/Principal	53	03/08/2018

Director	Title	Age	Since
Hao Wang BRD	Director/Board Member	57	20/07/2018
Yun Feng Li BRD	Director/Board Member	49	20/07/2018
Shu Ge Jiao CHM	Chairman	60	20/07/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MABPHARM LIMITED	+7.32%	+14.29%	-6.38%	-21.43%	216M
ARGENX SE	-5.36%	-1.38%	+57.53%	+114.92%	57.55B
WUXI APPTEC CO., LTD.	-0.49%	+8.30%	+62.88%	+67.95%	47.08B
BIONTECH SE	+0.48%	+1.25%	-12.03%	-15.42%	22.92B
INSMED INCORPORATED	+3.60%	+6.94%	-3.10%	+411.77%	22.14B
WUXI BIOLOGICS (CAYMAN) INC.	+4.17%	+8.64%	+27.72%	-15.63%	16.33B
GENMAB A/S	+0.29%	+4.76%	+28.54%	-33.97%	15.97B
EXELIXIS, INC.	-0.02%	-1.46%	+18.38%	+158.51%	12.9B
PHARMAESSENTIA CORPORATION	0.00%	+10.49%	+130.14%	+273.89%	12.85B
MADRIGAL PHARMACEUTICALS, INC.	+0.11%	+2.44%	+81.43%	+116.03%	11.84B
Average	+1.01%	+5.55%	+38.51%	+105.66%	21.98B
Weighted average by Cap.	-0.75%	+6.24%	+44.17%	+112.43%

	2024	2025
Net sales	258M 298M 38.04M 33.42M 30.79M 28.82M 54M 3.6B 54.91M 370M 143M 1.77B 143M 140M 6.14B	646M 746M 95.17M 83.61M 77.04M 72.12M 135M 9.02B 137M 925M 358M 4.42B 357M 350M 15.37B
Net income	-128M -148M -18.85M -16.56M -15.26M -14.28M -26.76M -1.79B -27.21M -183M -70.91M -876M -70.75M -69.23M -3.04B	57.13M 65.99M 8.42M 7.39M 6.81M 6.38M 11.95M 797M 12.15M 81.8M 31.66M 391M 31.59M 30.91M 1.36B
Net Debt	222M 257M 32.74M 28.76M 26.5M 24.81M 46.48M 3.1B 47.26M 318M 123M 1.52B 123M 120M 5.29B	217M 251M 32.04M 28.14M 25.93M 24.28M 45.48M 3.03B 46.25M 311M 121M 1.49B 120M 118M 5.18B